Apr-26-17 Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic
Apr-24-17 Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
Apr-18-17 Antibe Therapeutics Provides Update on Clinical Development Program for its Lead Drug, ATB-346
Mar-31-17 Antibe Therapeutics Announces Grant of Stock Options
Mar-27-17 Antibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research
Mar-07-17 Antibe Therapeutics Announces Results of Annual General Meeting
Mar-01-17 Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results
Feb-24-17 Antibe Therapeutics Enters into Regional Licensing Deal
Feb-20-17 Antibe Therapeutics Engages MKR Group for U.S. Investor Relations
Jan-31-17 Antibe Therapeutics Announces the Launch of PentOS OI™ Max, its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery
Jan-18-17 Antibe Therapeutics Announces Change of Auditor to Ernst & Young
Dec-21-16 Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million
Dec-16-16 Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
Nov-29-16 Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results
Oct-25-16 Antibe Therapeutics Announces CEO Letter to Shareholders
Oct-17-16 Antibe Therapeutics Confirms Non-Addictive Properties for its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
Oct-14-16 Antibe Therapeutics Announces Payment in Kind Election
Oct-11-16 Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
Sep-22-16 ATB-346 Shows Promising Results in Experimental Melanoma
Sep-07-16 Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference